Incidence and Risk Factors for Community-acquired Hepatitis C Infection from Birth to 5 Years of Age in Rural Egyptian Children
Overview
Tropical Medicine
Authors
Affiliations
A prospective study in three Egyptian villages (A, B and C) having a high prevalence of hepatitis C virus (HCV) infection examined incidence of community-acquired HCV infection in children; 2852 uninfected infants were prospectively followed from birth for up to 5.5 years. Fifteen seroconverted for either HCV antibodies and/or HCV-RNA (incidence of 0.53%). Ten had both anti-HCV and HCV-RNA; four had only anti-HCV; and one had HCV-RNA in the absence of antibody. The incidence rate at all ages was 2.7/1000 person-years (PY). It was 3.8/1000 PY during infancy and 2.0/1000 PY for the 1-5-years age group. Hospitalization and low birth weight increased the risk of infection; while living in village B, the family having a higher socioeconomic status, and advanced maternal education were protective. Six of eight HCV-infected infants reported iatrogenic exposures (e.g. hospitalization, therapeutic injections, ear piercing) prior to infection whereas only 2/7 children older than 1 year reported these exposures. Having an HCV-positive mother was the only other reported risk in two of these older children. The virus cleared in six (40%) children by the end of follow-up. Health education targeting iatrogenic exposures and focusing on risk factors could reduce HCV infection in children in high-risk populations.
Hetta H, Mekky M, Zahran A, Abdel-Malek M, Ramadan H, Shafik E Vaccines (Basel). 2020; 8(3).
PMID: 32664587 PMC: 7565874. DOI: 10.3390/vaccines8030380.
Kouyoumjian S, Chemaitelly H, Abu-Raddad L Sci Rep. 2018; 8(1):1661.
PMID: 29374178 PMC: 5785953. DOI: 10.1038/s41598-017-17936-4.
Hepatitis C Virus in North Africa: An Emerging Threat.
Daw M, El-Bouzedi A, Ahmed M, Dau A, Agnan M ScientificWorldJournal. 2016; 2016:7370524.
PMID: 27610403 PMC: 5004010. DOI: 10.1155/2016/7370524.
Epidemiology of hepatitis C virus exposure in Egypt: Opportunities for prevention and evaluation.
Miller F, Elzalabany M, Hassani S, Cuadros D World J Hepatol. 2015; 7(28):2849-58.
PMID: 26668697 PMC: 4670957. DOI: 10.4254/wjh.v7.i28.2849.
Hepatitis C genotype 4: The past, present, and future.
Abdel-Ghaffar T, Sira M, Naghi S World J Hepatol. 2015; 7(28):2792-810.
PMID: 26668691 PMC: 4670951. DOI: 10.4254/wjh.v7.i28.2792.